On the Radar…

Cerapedics, Inc., a Westminster, Colorado company focused on enhancing bone repair, has raised a $14.5M second round of financing as reported on peHUB. The company previously raised $12.25M in early 2007 from OrbiMed Advisors. In the current round, OribMed Advisors were joined by NGN Capital. The company’s core product is iFACTOR, a bone graph substitute. iFACTOR works by combining a unique anorganic bone mineral (ABM) and small peptide, P-15, which operates by a novel mechanism of facilitating the attachment of integrins, which in turn signal new bone growth in osteogenic cells. The product offers both enhanced and predictable bone healing and reduced cost compared to conventional growth factors. iFACTOR bears a CE Mark (European regulatory approval), making it available for sale outside the US, but has not yet been approved by the FDA for orthopedic indications. No details were provided on the planned use of the proceeds from this additional financing.